Repatha(evolocumab)

High LDL cholesterol; reducing risk of heart attack, stroke, and coronary revascularization. PCSK9 inhibitor.

1 DTP program

From $239/mo cash · $25/mo copay card

1 platform

FDA-Approved Indications

Primary hyperlipidemia (including HeFH) to reduce LDL-CReduce risk of MI, stroke, and coronary revascularization in adults with established CVD

Available direct-to-patient (DTP) programs

Sorted by price, lowest first. Always verify eligibility and pricing directly with the manufacturer.

Lowest price option

via AmgenNow · Amgen

$239/mo cash · $25/mo copay card

Cash: $239/mo (65% off ~$688 retail). Copay card: $25/mo (commercially insured). No prior auth or step therapy required.

Eligibility

US patient with valid Rx. No income requirement. Government-insured must waive govt insurance for ALL Amgen Rx for the calendar year.

Must waive government insurance for all Amgen medications for the entire calendar year.

Last verified: Mar 2026

Not sure which Repatha program fits your situation?